Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

AMCAP Global Steers Global Finance Into the Agentic Era With Proprietary Multi-Model AI Framework

April 27, 2026

Simply Contact Launches AI Call Simulation Onboarding Program for Multilingual Contact Center Agents

April 27, 2026

Zoomex Announces Today a Major Market Shift as $20.6 Trillion in Liquidity Moves Across Crypto Derivatives Platforms in 2026

April 27, 2026

At Beijing Auto Show, JETOUR Seeks to Turn the SUV Into a Symbol of Modern Mobility

April 27, 2026

Lumissil Introduces IS32LT3136 32-Channel Linear LED Driver for Next-Generation Automotive OLED Lighting

April 27, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » U.S. And Europe On-body Injectors Market Analysis Report 2024-2030: On-Body Injectors Market Surges as Elderly Population Grows
Press Release

U.S. And Europe On-body Injectors Market Analysis Report 2024-2030: On-Body Injectors Market Surges as Elderly Population Grows

By News RoomAugust 20, 20246 Mins Read
U.S. And Europe On-body Injectors Market Analysis Report 2024-2030: On-Body Injectors Market Surges as Elderly Population Grows
Share
Facebook Twitter LinkedIn Pinterest Email

Dublin, Aug. 20, 2024 (GLOBE NEWSWIRE) — The “U.S. And Europe On-body Injectors Market Size, Share & Trends Analysis Report By Technology (Spring-based, Motor-driven, Rotary Pump), By Application (Diabetes, Cardiovascular Disease), By End Use, By Region, And Segment Forecasts, 2024 – 2030” report has been added to ResearchAndMarkets.com’s offering.

The U.S. and Europe on-body injectors market size is anticipated to reach USD 5.45 billion by 2030 and is projected to grow at a CAGR 11.27% from 2024 to 2030. Primarily, the rising incidence of chronic illnesses such as diabetes and cancer has amplified the demand for advanced drug delivery systems.

According to June 2024 data from the American Heart Association, over 184 million people, or more than 61% of the U.S. population, are projected to have some form of cardiovascular disease (CVD). Total CVD-related costs are expected to triple to USD 1.8 trillion by 2050. On-body injectors provide a convenient and less intrusive way to administer medications, appealing especially to patients needing regular self-administration, thereby enhancing treatment adherence and overall therapeutic effectiveness. Moreover, the increasing elderly population in these regions underscores the necessity for effective drug delivery solutions, further driving market expansion.

In addition, the regulatory environment in the U.S. and Europe has been supportive of the development and commercialization of on-body injectors. Regulatory bodies such as the FDA and EMA have established clear guidelines and streamlined approval processes for these devices, ensuring their safety and efficacy. This regulatory support has encouraged manufacturers to innovate and bring new products to market more swiftly. Furthermore, the harmonization of regulatory standards across these regions has facilitated easier market entry and expansion for global companies, contributing to the overall growth of the on-body injectors market.

Moreover, market players such as BD, Stevanato Group, and Coherus BioSciences are leading in innovation, introducing advanced on-body delivery systems. Developments include customizable dosing options, enhanced connectivity features, and improved user interfaces to optimize patient convenience and treatment adherence. These advancements cater to the rising demand for efficient drug delivery solutions, particularly in managing conditions such as diabetes and autoimmune diseases.

For instance, in October 2022, Nemera and Zollner entered into a partnership to create electronic drug delivery devices, commencing with Nemera’s Symbioze, a high-capacity wearable injection device. Under this collaboration, Zollner will manage the electronics and software development for the Symbioze device. Such collaborative efforts are crucial in addressing the complex needs of chronic disease management, thereby driving the growth of the on-body injectors market in the U.S. and Europe.

Furthermore, increasing investment in healthcare infrastructure and the rising adoption of advanced medical devices in both the U.S. and Europe have fostered market growth. Governments and private entities are allocating substantial resources to modernize healthcare facilities and improve patient care standards. This investment includes the adoption of cutting-edge medical technologies, such as on-body injectors, which streamline treatment processes and reduce hospital stays.

U.S. And Europe On-body Injectors Market Report Highlights

  • The spring-based segment held the largest share of 40.89% in 2023, spring-based on-body injectors are effective devices offering numerous benefits to both patients and healthcare providers. One of the primary factors contributing to the market growth includes the increasing prevalence of chronic diseases such as diabetes and autoimmune disorders, which require regular & precise medication delivery
  • The diabetes segment held the largest share of 25.45% in 2023. On-body injectors are effective tools in diabetes management because they ensure precise and consistent delivery of medication. The rising healthcare expenditure on diabetes care further supports the adoption of advanced technologies such as on-body injectors
  • The hospitals & clinics segment held the largest share of 46.76% in 2023. With the population expanding and aging, there is an increasing demand for healthcare services, especially for chronic ailments such as diabetes, cardiovascular diseases, and autoimmune disorders
  • U.S. on-body injectors market dominated the overall market and accounted for the 51.15%-revenue share in 2023, driven by several factors, including increased healthcare spending, government initiatives, and higher disposable incomes. Additionally, favorable reimbursement scenarios, a rise in chronic diseases requiring long-term care, and high per capita income are expected to further stimulate market expansion

Companies Featured

  • West Pharmaceutical Services, Inc.
  • BD
  • Stevanato Group
  • Enable Injections
  • Nemera
  • Debiotech SA
  • AbbVie, Inc.
  • Coherus BioSciences, Inc
  • Gerresheimer AG
  • E3D Elcam Drug Delivery Devices

Key Attributes:

Report Attribute Details
No. of Pages 99
Forecast Period 2023 – 2030
Estimated Market Value (USD) in 2023 $2.65 Billion
Forecasted Market Value (USD) by 2030 $5.45 Billion
Compound Annual Growth Rate 11.2%
Regions Covered Europe, United States

Key Topics Covered:

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Technology outlook
2.2.2. Application outlook
2.2.3. End Use outlook
2.3. Regional outlook
2.4. Competitive Insights

Chapter 3. U.S. and Europe On-body Injectors Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. U.S. and Europe On-body Injectors Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.2. PESTEL Analysis

Chapter 4. U.S. and Europe On-body Injectors Market: Technology Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. U.S. and Europe On-body Injectors Market: Technology Movement Analysis
4.3. U.S. and Europe On-body Injectors Market by Technology Outlook (USD Billion)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5. Spring-based
4.6. Motor-driven
4.7. Rotary Pump
4.8. Expanding Battery

Chapter 5. U.S. and Europe On-body Injectors Market: Application Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. U.S. and Europe On-body Injectors Market: Application Movement Analysis
5.3. U.S. and Europe On-body Injectors Market by Application Outlook (USD Billion)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. Oncology
5.6. Diabetes
5.7. Cardiovascular Disease
5.8. Autoimmune Disease

Chapter 6. U.S. and Europe On-body Injectors Market: End Use Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. U.S. and Europe On-body Injectors Market: End Use Movement Analysis
6.3. U.S. and Europe On-body Injectors Market by End Use Outlook (USD Billion)
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.5. Hospitals & Clinics
6.6. Home Care Settings
6.7. Others

Chapter 7. U.S. and Europe On-body Injectors Market: Regional Estimates & Trend Analysis
7.1. Regional Dashboard
7.2. Regional U.S. and Europe On-body Injectors Market movement analysis
7.3. U.S. and Europe On-body Injectors Market: Regional Estimates & Trend Analysis by Technology, Application & End-use
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
7.5. U.S.
7.6. Europe

Chapter 8. Competitive Landscape
8.1. Market Participant Categorization
8.2. Key Company Profiles
8.2.1. Company overview
8.2.2. Financial performance
8.2.3. Product benchmarking
8.2.4. Strategic initiatives

For more information about this report visit https://www.researchandmarkets.com/r/lwtl6l

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  • U.S. And European On-body Injectors Market

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

AMCAP Global Steers Global Finance Into the Agentic Era With Proprietary Multi-Model AI Framework

Simply Contact Launches AI Call Simulation Onboarding Program for Multilingual Contact Center Agents

Zoomex Announces Today a Major Market Shift as $20.6 Trillion in Liquidity Moves Across Crypto Derivatives Platforms in 2026

At Beijing Auto Show, JETOUR Seeks to Turn the SUV Into a Symbol of Modern Mobility

Lumissil Introduces IS32LT3136 32-Channel Linear LED Driver for Next-Generation Automotive OLED Lighting

Veson and Veracity by DNV partner to streamline verified emissions reporting and commercial voyage management

OMODA × VCT EMEA: Boundless Spirit, Esports Synergy – For Global Youth

Real-World Test of OMODA&JAECOO VPD: Mechanical Parking Spaces, Dead-End Roads, Mall Pickups – Can It Outperform an Experienced Driver?

WeRide and Lenovo Collaborate to Deploy 200,000 Autonomous Vehicles Globally Over Five Years

Editors Picks

Simply Contact Launches AI Call Simulation Onboarding Program for Multilingual Contact Center Agents

April 27, 2026

Zoomex Announces Today a Major Market Shift as $20.6 Trillion in Liquidity Moves Across Crypto Derivatives Platforms in 2026

April 27, 2026

At Beijing Auto Show, JETOUR Seeks to Turn the SUV Into a Symbol of Modern Mobility

April 27, 2026

Lumissil Introduces IS32LT3136 32-Channel Linear LED Driver for Next-Generation Automotive OLED Lighting

April 27, 2026

Latest News

Veson and Veracity by DNV partner to streamline verified emissions reporting and commercial voyage management

April 27, 2026

OMODA × VCT EMEA: Boundless Spirit, Esports Synergy – For Global Youth

April 27, 2026

Real-World Test of OMODA&JAECOO VPD: Mechanical Parking Spaces, Dead-End Roads, Mall Pickups – Can It Outperform an Experienced Driver?

April 27, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version